Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Product Monograph Comparisons
-
We understand the guidelines regarding what can and can't be included in a PM comparison of several products. This question is limited to the products included in the comparison. Let's say the table is a comparison of a specific drug class with the same indication and that there are about 10 products on the market. What does PAAB require as support that some products do not need to be included in the table? What are the guidelines to determine what products need to be included in the comparison and what products can be excluded? Or is at the discretion of the manufacturer developing the table?
-
Hello @lags
This is a complex question that would be better suited as an opinion submission where details on the therapeutic area, class of products, proposed inclusion and exclusion criteria etc. could be provided. It is not possible to create an exhaustive list that would be clear enough to apply across all therapeutic areas. As a general response, any selection criteria that have eliminated other products from the presentation, should be clearly conveyed along with disclosure to the audience that this is a selective presentation.
